Fundraising Fox

Plasmology4

Scottsdale, US · Founded 2010 · Nevada corporation

Plasmology4 develops Plaz4, a non-thermal (cold) plasma technology for medical applications, with its first product, the Plaz4 1000 system, aimed at treating antibiotic-resistant infections and chronic non-healing wounds. It is a pre-revenue medical device company in the emerging field of plasma medicine, and its lead product has received FDA Breakthrough Device designation but is not yet approved for sale.

Deep TechHealthtechMedical Devices

Founders & leadership

RHRobert Hummel
Robert HummelinChief Executive Officer
MJMarc Jacofsky
Marc JacofskyinChief Scientific Officer
GWGreg Watson
Greg WatsoninChief Innovation Officer
RD
RONALD D ROBINSONSECRETARY AND DIRECTOR

Board

AW
ANDREW W MILLER JR.Board director
SA
STEPHEN A BRIGIDOBoard director
RW
ROY W SANDERSBoard director
KP
KEVIN P MCDOWELLBoard director
JR
JAMES R LAWSONBoard director
DJ
David JacofskyChairman of the Board of Directors
RL
RON LAWSONBoard director

Reported raises · per SEC filings

Form D private placements

$4M disclosed across 7 rounds · 2012–2016

▶$250KraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert M HummelExecutive Officer, Director
  • David J JacofskyExecutive Officer, Director
  • Stephen A BrigidoDirector
  • James R LawsonDirector
  • Andrew W Miller Jr.Director
  • Kevin P McDowellDirector
  • Gregory A WatsonExecutive Officer, Director
  • Ronald D RobinsonExecutive Officer, Director
  • Marc C JacofskyExecutive Officer
Offering amount
$2M
Amount sold
$250K
First sale
Dec 2016
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedApr 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • GREGORY A WATSONExecutive Officer, Director
  • ANDREW W MILLER JR.Director
  • MARC C JACOFSKYExecutive Officer
  • KEVIN P MCDOWELLDirector
  • ROBERT M HUMMELExecutive Officer, Director
  • ROY W SANDERSDirector
  • STEPHEN A BRIGIDODirector
  • RONALD D ROBINSONExecutive Officer, Director
  • JAMES R LAWSONDirector
  • DAVID J JACOFSKYExecutive Officer, Director
Offering amount
$5M
Amount sold
$125K
First sale
Mar 2016
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedDec 2015 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • ROBERT M HUMMELExecutive Officer, Director
  • ROY W SANDERSDirector
  • MARC C JACOFSKYExecutive Officer
  • GREGORY A WATSONExecutive Officer, Director
  • STEPHEN A BRIGIDODirector
  • ANDREW W MILLER JR.Director
  • RONALD D ROBINSONExecutive Officer, Director
  • JAMES R LAWSONDirector
  • DAVID J JACOFSKYExecutive Officer, Director
  • KEVIN P MCDOWELLDirector
Offering amount
$1M
Amount sold
$1M
First sale
Dec 2015
Incorporated
Corporation, Nevada, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedSep 2015 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • ANDREW W MILLER JR.Director
  • DAVID J JACOFSKYExecutive Officer, Director
  • GREGORY A WATSONExecutive Officer, Director
  • STEPHEN A BRIGIDODirector
  • MARC C JACOFSKYExecutive Officer
  • ROY W SANDERSDirector
  • RONALD D ROBINSONExecutive Officer, Director
  • ROBERT M HUMMELExecutive Officer, Director
  • KEVIN P MCDOWELLDirector
  • JAMES R LAWSONDirector
Offering amount
$3M
Amount sold
$300K
Minimum investment
$200K
First sale
Aug 2015
Incorporated
Corporation, Nevada, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedJul 2014 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • GREGORY A WATSONExecutive Officer, Director
  • ANDREW W MILLER JR.Director
  • ROY SANDERSDirector
  • STEPHEN A BRIGIDODirector
  • ROBERT M HUMMELExecutive Officer, Director
  • RON LAWSONDirector
  • MARC C JACOFSKYExecutive Officer
  • RONALD ROBINSONExecutive Officer, Director
  • DAVID J JACOFSKYExecutive Officer, Director
Offering amount
$5M
Amount sold
$300K
Minimum investment
$250K
First sale
Jul 2014
Incorporated
Corporation, Nevada, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJun 2014 · 1 investors · Other Health Care
Rule 506(c)
Officers, directors & promoters on the filing
  • MARC C JACOFSKYExecutive Officer
  • ROY SANDERSDirector
  • GREGORY A WATSONExecutive Officer, Director
  • ROBERT M HUMMELExecutive Officer, Director
  • RON LAWSONDirector
  • STEPHEN A BRIGIDODirector
  • DAVID J JACOFSKYExecutive Officer, Director
  • ANDREW W MILLER JR.Director
  • RONALD ROBINSONExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2M
First sale
Jun 2014
Incorporated
Corporation, Nevada, 2010
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$40KraisedJan 2012 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • RONALD ROBINSONExecutive Officer, Director
  • RON LAWSONDirector
  • KEVIN MCDOWELLDirector
  • DAVID J JACOFSKYExecutive Officer, Director
  • GREGORY A WATSONDirector
Offering amount
$3M
Amount sold
$40K
First sale
Jan 2012
Incorporated
Corporation, Nevada, 2010
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Doximity5 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies competing with Plasmology4 for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Plasmology4 do?
Plasmology4 develops Plaz4, a non-thermal (cold) plasma technology for medical applications, with its first product, the Plaz4 1000 system, aimed at treating antibiotic-resistant infections and chronic non-healing wounds. It is a pre-revenue medical device company in the emerging field of plasma medicine, and its lead product has received FDA Breakthrough Device designation but is not yet approved for sale.
How much funding has Plasmology4 raised?
Plasmology4 has disclosed $4M raised across 7 rounds.
Where is Plasmology4 headquartered?
Plasmology4 is headquartered in Scottsdale, US.